CVS Health (NYSE:CVS) Price Target Raised to $73.00

CVS Health (NYSE:CVS) had its target price boosted by analysts at Wells Fargo & Company from $68.00 to $73.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the pharmacy operator’s stock. Wells Fargo & Company‘s price target indicates a potential upside of 11.36% from the company’s previous close.

Several other research firms have also issued reports on CVS. Evercore ISI upped their target price on CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Monday, January 27th. UBS Group reduced their price objective on CVS Health from $62.00 to $59.00 and set a “neutral” rating for the company in a research note on Tuesday. Deutsche Bank Aktiengesellschaft raised CVS Health from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a research report on Tuesday, December 3rd. Barclays increased their price target on shares of CVS Health from $71.00 to $73.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Piper Sandler lowered their price objective on shares of CVS Health from $72.00 to $64.00 and set an “overweight” rating on the stock in a research report on Monday, November 25th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $70.28.

CVS Health Stock Up 3.7 %

NYSE CVS traded up $2.34 on Thursday, reaching $65.56. The company had a trading volume of 4,232,193 shares, compared to its average volume of 12,933,698. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80. The stock has a market capitalization of $82.50 billion, a P/E ratio of 16.60, a P/E/G ratio of 0.60 and a beta of 0.61. The company’s fifty day moving average is $50.71 and its 200 day moving average is $55.94. CVS Health has a 52-week low of $43.56 and a 52-week high of $80.75.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. Sell-side analysts anticipate that CVS Health will post 5.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CVS Health

Several hedge funds have recently bought and sold shares of the company. MidAtlantic Capital Management Inc. purchased a new position in shares of CVS Health during the 3rd quarter valued at $25,000. Ridgewood Investments LLC boosted its stake in CVS Health by 255.7% during the fourth quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator’s stock valued at $28,000 after buying an additional 450 shares during the period. Stonebridge Financial Group LLC purchased a new position in CVS Health during the fourth quarter worth about $28,000. Hopwood Financial Services Inc. bought a new position in CVS Health in the 4th quarter worth about $29,000. Finally, Livelsberger Financial Advisory purchased a new stake in shares of CVS Health in the 3rd quarter valued at about $31,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.